BofA warns Fed risks policy mistake with early rate cuts
On Monday, Truist Securities adjusted its financial outlook for Perspective Therapeutics Inc (NYSE:CATX), reducing the price target to $10 from the previous $21 while sustaining a Buy rating on the shares. The stock, currently trading at $1.74, has experienced significant pressure, falling over 87% in the past year. The revision follows the company's fourth-quarter 2024 results and updated timelines for commercial launches. According to InvestingPro data, analyst targets range from $6 to $21, with a strong consensus Buy recommendation.
Perspective Therapeutics concluded the fourth quarter of 2024 with approximately $227 million in cash, cash equivalents, and short-term investments. According to the company, these funds are expected to support its clinical efforts well into late 2026. InvestingPro analysis shows the company holds more cash than debt on its balance sheet, with a strong current ratio of 12.68, though it's quickly burning through cash. For deeper insights into CATX's financial health and 12 additional ProTips, explore InvestingPro's comprehensive research report. Truist Securities made changes to its model after consulting with the company's management, which included amending the launch curve timelines for Perspective's leading assets. This adjustment was necessary due to the pace of the dose escalation trials for two clinical programs targeting neuro-endocrine tumors and melanoma.
The modifications to the Phase 1 studies for both clinical programs, specifically the dosing adjustments, have led to a delay in the commercialization timelines. Consequently, the anticipated peak sales for the year 2035 have been revised to approximately $600 million, a decrease from the prior estimate of around $900 million.
The new price target of $10 reflects the updated projections and changes made to Truist's model. Despite the lowered price target, Truist Securities maintains a Buy rating on Perspective Therapeutics, indicating a continued positive outlook on the stock's potential.
In other recent news, Perspective Therapeutics Inc has been the focus of several analyst updates and financial assessments. The company reported a year-ending cash balance of $227 million, which is expected to support its operations through late 2026, providing a stable financial runway for ongoing research and development efforts. Oppenheimer analysts maintained an Outperform rating with a $16 target, citing the company's financial stability and the expansion of its VMT-α-NET trial as positive indicators. Scotiabank (TSX:BNS) also initiated coverage with a Sector Outperform rating and a $15 price target, highlighting the company's unique position as an independent player in the radiopharmaceutical space.
Lucid (NASDAQ:LCID) Capital Markets raised its price target to $20, up from $15, while maintaining a Buy rating, following the presentation of promising new data from Perspective Therapeutics' VMT-α-NET trial. The data suggested the potential for the drug to be best-in-class, addressing previous concerns and boosting investor confidence. Analysts from Lucid Capital Markets noted the potential for further positive data and higher dosing possibilities, reinforcing their optimistic outlook. These developments reflect a broad confidence among analysts in Perspective Therapeutics' future prospects and its ongoing clinical trials.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.